Fred Grossman

Company: Coya Therapeutics

Job title: President & Chief Medical Officer

Seminars:

Coya 302: A Dual Mechanism Potential Biological Immunotherapy for ALS and FTD 11:30 am

Treg dysfunction as a core driver of neurodegeneration in ALS and FTD Coya 302 targets adaptive and innate immune pathways Coya 302 as potential therapy for ALS and FTDRead more

day: Conference Day Two